Product characterization
| Patient ID . | B cells CD19+ . | T cells CD3+ . | CD4+ CD3+ . | CD8+ CD3+ . | CD3+ CD16+ CD56+ . | CD3- CD56+ CD16+ . | CD3+ TCRab . | CD3+ TCRgd . | Mono CD14+ . | DCs CD83+ CD3- . | Actin . | WT1 . | Prame . | Survivin . | TAA∗ . | Fold expansion . | Total No. of cells Frozen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage (%) | Average Spot Forming Units per well | ||||||||||||||||
| P1 | 0 | 99.5 | 10.9 | 29.3 | 42 | 0 | 16.3 | 73.5 | 0.3 | 0 | 7 | 14 | 182 | 2 | 156 | 23.2 | 1.39x108 |
| P2 | 0.2 | 99.1 | 16.9 | 81.6 | 2.2 | 0.3 | 91.8 | 0.69 | 0.2 | 0 | 1 | 0.5 | 5 | 0 | 5.5 | 12.3 | 2.45x108 |
| P3 | 1.58 | 84.9 | 10.2 | 74.6 | 52.3 | 0.92 | 80.3 | 4.1 | 1.08 | 0.16 | 154.5 | 139 | 696.7 | 132.5 | 741.6 | 5.91 | 1.36x108 |
| P4 | 0 | 84.5 | 20 | 39 | 25 | 0.52 | 66 | 23.1 | 0 | 0 | 5.5 | 10.5 | 72.5 | 5 | 48 | 5 | 1.0x108 |
| P5 | 0.05 | 83.3 | 1.74 | 42.7 | 23.7 | 14.8 | 45.3 | 42.2 | 0.01 | 0.04 | 3.5 | 5 | 4 | 1 | 25.5 | 4.92 | 9.35x107 |
| P6 | 0.1 | 80.9 | 4.8 | 69.6 | 27.9 | 16.8 | 82.7 | 12.3 | 0 | 0 | 2.5 | 16 | 234 | 2 | 182.5 | 3.86 | 1.39x108 |
| P6_2 | 0 | 97.3 | 7.1 | 77 | 58.3 | 2.6 | 71.9 | 26 | 0 | 0 | 7.5 | 15 | 12 | 5 | 27 | 4.1 | 4.95x107 |
| P7 | 0 | 99.3 | 10.4 | 85.4 | 1.44 | 0.17 | 94.1 | 4 | 0 | 0 | 18.5 | 24.5 | 15.5 | 30 | 20.5 | 5.57 | 3.34x107 |
| P7_2 | 0.07 | 96 | 20 | 75.7 | 45.1 | 4.15 | 87.4 | 11.5 | 0 | 0.02 | 12.5 | 8 | 10 | 6 | 9 | 1.83 | 1.30x108 |
| P8 | 0.3 | 98 | 1.73 | 43.3 | 33.7 | 1.1 | 39.5 | 58 | 0.1 | 0 | 7.5 | 37 | 67 | 18 | 22 | 5.97 | 1.88x108 |
| P9 | 0.05 | 98.3 | 9.5 | 87.5 | 11.2 | 0.6 | 97.5 | 1.9 | 0 | 0.02 | 9.5 | 11 | 16 | 9 | 11.5 | 6.52 | 1.37x108 |
| P10 | 0.09 | 99.5 | 11.8 | 69.5 | 3.59 | 0 | 81.4 | 16.1 | 0 | 0 | 1.5 | 15.5 | 1 | 14 | 10.5 | 2.31 | 4.38x107 |
| Patient ID . | B cells CD19+ . | T cells CD3+ . | CD4+ CD3+ . | CD8+ CD3+ . | CD3+ CD16+ CD56+ . | CD3- CD56+ CD16+ . | CD3+ TCRab . | CD3+ TCRgd . | Mono CD14+ . | DCs CD83+ CD3- . | Actin . | WT1 . | Prame . | Survivin . | TAA∗ . | Fold expansion . | Total No. of cells Frozen . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage (%) | Average Spot Forming Units per well | ||||||||||||||||
| P1 | 0 | 99.5 | 10.9 | 29.3 | 42 | 0 | 16.3 | 73.5 | 0.3 | 0 | 7 | 14 | 182 | 2 | 156 | 23.2 | 1.39x108 |
| P2 | 0.2 | 99.1 | 16.9 | 81.6 | 2.2 | 0.3 | 91.8 | 0.69 | 0.2 | 0 | 1 | 0.5 | 5 | 0 | 5.5 | 12.3 | 2.45x108 |
| P3 | 1.58 | 84.9 | 10.2 | 74.6 | 52.3 | 0.92 | 80.3 | 4.1 | 1.08 | 0.16 | 154.5 | 139 | 696.7 | 132.5 | 741.6 | 5.91 | 1.36x108 |
| P4 | 0 | 84.5 | 20 | 39 | 25 | 0.52 | 66 | 23.1 | 0 | 0 | 5.5 | 10.5 | 72.5 | 5 | 48 | 5 | 1.0x108 |
| P5 | 0.05 | 83.3 | 1.74 | 42.7 | 23.7 | 14.8 | 45.3 | 42.2 | 0.01 | 0.04 | 3.5 | 5 | 4 | 1 | 25.5 | 4.92 | 9.35x107 |
| P6 | 0.1 | 80.9 | 4.8 | 69.6 | 27.9 | 16.8 | 82.7 | 12.3 | 0 | 0 | 2.5 | 16 | 234 | 2 | 182.5 | 3.86 | 1.39x108 |
| P6_2 | 0 | 97.3 | 7.1 | 77 | 58.3 | 2.6 | 71.9 | 26 | 0 | 0 | 7.5 | 15 | 12 | 5 | 27 | 4.1 | 4.95x107 |
| P7 | 0 | 99.3 | 10.4 | 85.4 | 1.44 | 0.17 | 94.1 | 4 | 0 | 0 | 18.5 | 24.5 | 15.5 | 30 | 20.5 | 5.57 | 3.34x107 |
| P7_2 | 0.07 | 96 | 20 | 75.7 | 45.1 | 4.15 | 87.4 | 11.5 | 0 | 0.02 | 12.5 | 8 | 10 | 6 | 9 | 1.83 | 1.30x108 |
| P8 | 0.3 | 98 | 1.73 | 43.3 | 33.7 | 1.1 | 39.5 | 58 | 0.1 | 0 | 7.5 | 37 | 67 | 18 | 22 | 5.97 | 1.88x108 |
| P9 | 0.05 | 98.3 | 9.5 | 87.5 | 11.2 | 0.6 | 97.5 | 1.9 | 0 | 0.02 | 9.5 | 11 | 16 | 9 | 11.5 | 6.52 | 1.37x108 |
| P10 | 0.09 | 99.5 | 11.8 | 69.5 | 3.59 | 0 | 81.4 | 16.1 | 0 | 0 | 1.5 | 15.5 | 1 | 14 | 10.5 | 2.31 | 4.38x107 |
Data for additional product runs for individual patients are labeled as “Patient(no.)_2.“
TAA represents Spot forming cells (SFC) in response to mixture of WT1, PRAME and Survivin added to the same experimental well.